Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells

Rebeka Sultana(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Christina J. Perry(Macquarie University), Stephen Chan(Heidelberg University), Tarek M.A. Abdel-Fatah(University of Nottingham), Nada Albarakti(University of Nottingham), Vivek Chandra mohan(University of Nottingham), Claire Seedhouse(University of Nottingham)
PLoS ONE
February 25, 2013
10.1371/journal.pone.0057098
Cited by 85

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374